The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2186 participants.

Also called NCT02562183

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,186 participants (planned count) (from the registry)
Sponsor
Techpool Bio-Pharma Co., Ltd. (from the registry)
Registry
  • NCT NCT02562183
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02562183. Allocation not applicable; no masking; primary purpose treatment. Start 2015-08 (registry gives no type); primary completion 2018-11-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein
Condition
Cerebral Infarction
Intervention (Drug)
kallikrein
Lead sponsor
Techpool Bio-Pharma Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02562183
Content hash
b18b530e4df452b6f0802be7f5427af0fe50e3babe2030f4f582f175e6eff3cf